Brazil Medical Cannabis Market Nears R$1 Billion
Medical staff reviewing imported cannabis products and inventory in Brazil
Brazil medical cannabis market growth is becoming one of the strongest international cannabis business signals right now. International Cannabis Business Conference reports that Brazil’s legal medical cannabis sector generated R$970.9 million in 2025 and reached about 873,000 patients in treatment. The article also notes that medical cannabis therapies are now available in an estimated 85 percent of Brazilian municipalities, more than 55,000 doctors and qualified professionals have prescribed cannabis based medications since 2019, and imports reached historic levels earlier this year. For operators, investors, medical cannabis companies, healthcare providers, and compliance teams, Brazil is no longer just an emerging market to watch. It is becoming a serious growth market with real patient demand.
Quick facts
• Brazil’s legal medical cannabis market generated R$970.9 million in 2025
• Kaya Mind reported 873,111 medical cannabis patients in Brazil in 2025
• That patient count represented about 30 percent growth compared with 2024
• ICBC reports that medical cannabis therapies are available in about 85 percent of Brazilian municipalities
• More than 55,000 doctors and qualified professionals have prescribed cannabis based medications since 2019
• Brazil’s medical cannabis imports grew 60.1 percent in March 2026 compared with March 2025
• Anvisa granted more than 61,000 import authorizations in the first quarter of 2026
• March 2026 alone accounted for 23,199 import authorizations
• The universal operator lesson is simple: Brazil’s opportunity is real, but import rules, physician access, product registration, and regulated supply will decide who captures it
If Brazil market exposure is affecting your growth plan, complete our quick Cannashield intake form so you can map import, product, compliance, and insurance exposure before patient demand grows faster than your operating structure.
Why Brazil’s market value matters
The R$970.9 million market figure matters because it shows that Brazil’s medical cannabis sector is moving from early adoption into measurable scale. Many international markets have policy momentum, but not all have patient volume, physician activity, and import demand moving together. Brazil does.
The patient count is especially important. Kaya Mind reported that Brazil reached 873,111 medical cannabis patients in 2025, up about 30 percent from the prior year. That gives operators and investors a clearer demand signal than legislation alone. A market with nearly one million patients can support product strategy, distribution planning, physician education, and long term capital interest.
But market value alone does not mean easy access. Brazil’s structure is still shaped by regulation, import pathways, prescriptions, product cost, and uneven patient affordability. Growth is visible, but execution still depends on navigating the system correctly.
Why imports still control the opportunity
Imports remain one of the most important parts of Brazil’s medical cannabis story. ICBC cited data showing March 2026 medical cannabis imports grew 60.1 percent compared with March 2025, while Anvisa granted more than 61,000 import authorizations in the first quarter of 2026. March alone reached 23,199 authorizations.
That matters because import dependence creates opportunity for international suppliers, but it also creates friction. Products need documentation, patient authorization, prescription support, logistics planning, customs readiness, quality records, and a clear path through Anvisa rules. Companies that only see the demand number may underestimate how much operational discipline is required.
This is the universal operator lesson. In a medical import market, demand is not enough. The winning companies are the ones that can move compliant product through a controlled health system.
Why physicians shape the market
Brazil’s growth is also tied to physician participation. ICBC reports that more than 55,000 doctors and qualified professionals have prescribed cannabis based medications in Brazil since 2019. That is a major access signal because medical cannabis demand depends on more than patient interest. Patients need prescribers who understand eligibility, dosing, product type, safety, and documentation.
For healthcare providers and medical cannabis companies, education becomes a core market function. Physicians need credible information, not exaggerated claims. Patients need guidance on product selection, dosage, adverse effects, drug interactions, and what to expect. Operators need to avoid treating medical demand like consumer retail demand.
That is especially important in Brazil because patient access may vary by municipality, income level, product cost, and provider familiarity. A market can be large and still unequal.
Why investors should watch regulation
Brazil’s regulatory environment is also changing. Anvisa published new rules in February 2026 covering medical cannabis production, manufacturing, and import frameworks. Reuters previously reported that Anvisa also approved Embrapa, Brazil’s agricultural research agency, to conduct cannabis research, including seed bank and genetic development work.
That suggests Brazil may gradually reduce some import dependence over time if domestic production and research pathways mature. For investors, that creates both opportunity and uncertainty. Import focused companies may benefit now, while longer term market structure could shift if local production expands, product registration improves, and domestic supply becomes more realistic.
If you need to organize import, product, physician, and insurance records before entering or expanding in Brazil, use the Cannashield intake form to identify weak points and build a clearer market entry file.
Conclusion
Brazil’s medical cannabis market is becoming one of the most important international cannabis growth stories. The sector generated R$970.9 million in 2025, patient counts are rising, import authorizations are hitting records, and physician participation continues to expand.
For operators, investors, medical cannabis companies, exporters, healthcare providers, and compliance teams, the message is simple. Brazil is a serious opportunity, but not a simple one. The companies most likely to win will understand imports, patient access, physician education, product quality, local regulation, and the shift toward a more mature medical supply chain.
Educational note: This article is for education only and is not legal, regulatory, medical, tax, financial, import, product safety, or insurance advice.
What to do this week
• Review whether Brazil fits your medical cannabis export, investment, or patient access strategy
• Map import authorization requirements, prescription workflows, and Anvisa documentation expectations
• Review product files, quality records, certificates, labels, and supply chain readiness
• Track physician education needs and patient access gaps by region
• Watch whether local production rules and research approvals shift long term supply strategy
• Build a short internal memo on Brazil market size, import dependence, physician access, and compliance risk
FAQ
How much was Brazil’s legal medical cannabis market worth in 2025?
ICBC reported that Brazil’s legal medical cannabis market generated R$970.9 million in 2025.
How many medical cannabis patients did Brazil have in 2025?
Kaya Mind reported 873,111 patients using cannabis based products in Brazil in 2025.
How fast is the patient market growing?
Kaya Mind reported about 30 percent growth compared with 2024.
Why are imports important in Brazil?
Brazil still relies heavily on imported medical cannabis products, and Anvisa import authorizations reached record levels in early 2026.
How many import authorizations did Anvisa grant in Q1 2026?
ICBC reported that Anvisa granted more than 61,000 import authorizations in the first quarter of 2026.
What is the biggest operator takeaway?
Brazil is becoming a serious medical cannabis growth market, but success depends on import rules, physician education, patient access, product documentation, and regulated supply.
Professionals reviewing Brazil medical cannabis market growth and imports
You might also like
SOURCES
International Cannabis Business Conference, How Much Is Brazil’s Medical Cannabis Market Worth?
https://internationalcbc.com/how-much-is-brazils-medical-cannabis-market-worth/
Kaya Mind, Número de pacientes de cannabis no Brasil em 2025
https://kayamind.com/numero-pacientes-cannabis-brasil-2025/
Anvisa, Importação de produtos derivados de Cannabis
https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/controlados/cannabis
Brazil’s legal medical cannabis market generated R$970.9 million in 2025 and reached more than 873,000 patients in treatment. The bigger lesson is that Brazil is becoming a serious international growth market, but imports, physician education, patient access, product documentation, and regulation will decide who captures the opportunity.